Author

Stella Hughes

Observed names: Hughes Stella, Hughes, Stella, Hughes, Stella

Institutions: Belfast Health and Social Care Trust, The University of Melbourne, Belfast City Hospital, Royal Victoria Hospital

Observed institutions: Belfast Health and Social Care Trust, The Royal Melbourne Hospital, Box Hill Hospital, University of Ulster, Burnet Institute, The University of Melbourne, Musgrave Park Hospital, Craigavon Area Hospital, The Alfred Hospital, University Hospitals Coventry and Warwickshire NHS Trust, John Radcliffe Hospital, Belfast City Hospital, Karolinska Institutet, University of Oxford, Royal Victoria Hospital, Royal Victoria Hospital, Alfred Health, Monash University, Newcastle University

OpenAlex ID: A5114041016

Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

2020 · Tomas Kalincik, Ibrahima Diouf, et al. · Neurology · 109

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

2023 · Izanne Roos, Stella Hughes, et al. · JAMA Neurology · 73

PDF

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

2023 · Tomas Kalincik, Sifat Sharmin, et al. · JAMA Neurology · 67

PDF

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis

2025 · Jannis Müller, Sifat Sharmin, et al. · JAMA Neurology · 66

PDF

Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines

2022 · Ruth Dobson, David Rog, et al. · Practical Neurology · 66

PDF

COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies

2021 · Afagh Garjani, Rodden M Middleton, et al. · Multiple Sclerosis and Related Disorders · 59

PDF

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses

2023 · Benedict D. Michael, Cordelia Dunai, et al. · Nature Communications · 50

PDF

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

2017 · Alessio Signori, Guillermo Izquierdo, et al. · Multiple Sclerosis Journal · 48

Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register

2020 · Nikos Evangelou, Afagh Garjani, et al. · Journal of Neurology Neurosurgery & Psychiatry · 42

PDF

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

2023 · Sifat Sharmin, Izanne Roos, et al. · Brain · 31

PDF

Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies

2024 · Wei Z. Yeh, Anneke Van Der Walt, et al. · Neurology Neuroimmunology & Neuroinflammation · 28

PDF

Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study

2024 · Edward De Brouwer, Thijs Becker, et al. · PLOS Digital Health · 26

Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case–control study of the UK MS Register

2021 · Afagh Garjani, Rachael Hunter, et al. · Multiple Sclerosis Journal · 25

PDF

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry

2021 · Helmut Butzkueven, Tim Spelman, et al. · European Journal of Neurology · 24

PDF

Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype

2019 · Yuan Zhou, Suzi B Claflin, et al. · Multiple Sclerosis Journal · 18

CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis

2020 · Michelle Naughton, Jill Moffat, et al. · Journal of Neuroinflammation · 17

PDF

Confirmed disability progression as a marker of permanent disability in multiple sclerosis

2022 · Sifat Sharmin, Francesca Bovis, et al. · European Journal of Neurology · 16

PDF

Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

2025 · Ashkan Pirmani, Edward De Brouwer, et al. · npj Digital Medicine · 15

PDF

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

2023 · Cyrus Daruwalla, Vahid Shaygannejad, et al. · Multiple Sclerosis Journal · 15

PDF

Reduced Cone Density Is Associated with Multiple Sclerosis

2023 · Gemma McIlwaine, Lajos Csincsik, et al. · Ophthalmology Science · 14

Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus

2023 · Priyanka Iyer, Kate Wiles, et al. · Multiple Sclerosis Journal · 11

Predictors of treatment switching in the Big Multiple Sclerosis Data Network

2023 · Tim Spelman, Melinda Magyari, et al. · Frontiers in Neurology · 9

PDF

Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

2023 · Ibrahima Diouf, Charles B Malpas, et al. · Journal of Neurology Neurosurgery & Psychiatry · 9

PDF

Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

2023 · Ibrahima Diouf, Charles B. Malpas, et al. · European Journal of Neurology · 9

PDF

2025 · Jessica Shipley, Heidi N. Beadnall, et al. · JAMA Network Open · 7

PDF

Works count: 96

Citation count: 897

H-index: 16

I10-index: 21